OAB agent demonstrates efficacy, tolerability in phase 3 trial

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2011年 / 46卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：287 / 287
页数：1
相关论文
共 50 条
  • [1] University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL
    Galanina, Natalie
    Smith, Sonali M.
    Liao, Chuanhong
    Petrich, Adam
    Libao, Bernadette
    Gartenhaus, Ronald
    Westin, Jason R.
    Cohen, Kenneth S.
    Knost, James A.
    Stadler, Walter M.
    Doyle, Austin
    Karrison, Theodore
    Gordon, Leo I.
    Evens, Andrew M.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (02) : 264 - 267
  • [2] Ozanimod demonstrates efficacy and safety in a phase 3 trial of relapsing multiple sclerosis (SUNBEAM)
    Comi, G.
    Kappos, L.
    Selmaj, K. W.
    Bar-Or, A.
    Arnold, D. L.
    Steinman, L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E.
    Cree, B. A. C.
    Sheffield, J. K.
    Raghupathi, K.
    Cohen, J. A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 73 - 74
  • [3] Ozanimod Demonstrates Efficacy and Safety in a Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM)
    Comi, Giancarlo
    Arnold, Douglas L.
    Cree, Bruce A. C.
    Kappos, Ludwig
    Selmaj, Krzysztof W.
    Bar-Or, Amit
    Steinman, Lawrence
    Hartung, Hans-Peter
    Montalban, Xavier
    Havrdova, Eva K.
    Sheffield, James K.
    Raghupathi, Kartik
    Cohen, Jeffrey A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 20 - 21
  • [4] Phase II trial demonstrates efficacy of erythropoietin in optic neuritis
    [J]. Nature Reviews Neurology, 2012, 8 (5) : 239 - 239
  • [5] Efficacy and tolerability of bazedoxifene in Mexican women with osteoporosis: a subgroup analysis of a randomized phase 3 trial
    Palacios, Santiago
    Williams, Robert
    Mirkin, Sebastian
    Pan, Kaijie
    Arias, Lizbeth
    Komm, Barry S.
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2016, 23 (07): : 771 - 777
  • [6] Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability
    Berry, James D.
    Paganoni, Sabrina
    Atassi, Nazem
    Macklin, Eric A.
    Goyal, Namita
    Rivner, Michael
    Simpson, Ericka
    Appel, Stanley
    Grasso, Daniela L.
    Mejia, Nicte I.
    Mateen, Farrah
    Gill, Alan
    Vieira, Fernando
    Tassinari, Valerie
    Perrin, Steven
    [J]. MUSCLE & NERVE, 2017, 56 (06) : 1077 - 1084
  • [7] EFFICACY AND TOLERABILITY OF GLAUCINE AS AN ANTITUSSIVE AGENT
    GASTPAR, H
    CRISCUOLO, D
    DIETERICH, HA
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 1984, 9 (01) : 21 - 27
  • [8] Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
    Ragon, Brittany Knick
    Kantarjian, Hagop
    Jabbour, Elias
    Ravandi, Farhad
    Cortes, Jorge
    Borthakur, Gautam
    DeBose, LaKiesha
    Zeng, Zhihong
    Schneider, Heather
    Pemmaraju, Naveen
    Garcia-Manero, Guillermo
    Kornblau, Steven
    Wierda, William
    Burger, Jan
    DiNardo, Courtney D.
    Andreeff, Michael
    Konopleva, Marina
    Daver, Naval
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (01) : 7 - 11
  • [9] Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β3-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB)
    Rossanese, Marta
    Novara, Giacomo
    Challacombe, Ben
    Iannetti, Alessandro
    Dasgupta, Prokar
    Ficarra, Vincenzo
    [J]. BJU INTERNATIONAL, 2015, 115 (01) : 32 - 40
  • [10] Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist:: an investigation of warning time in patients with OAB
    Zinner, N
    Susset, J
    Gittelman, M
    Arguinzoniz, M
    Rekeda, L
    Haab, F
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (01) : 119 - 126
12345